THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Wary et al.

§ ART UNIT:

FILED: March 29, 2004

§ §

EXAMINER:

§

§

SERIAL NO.: 10/812,238

§

FOR: Uses of Vascular Endothelial Growth Factor and Type 1 Collagen Inducible

§ §

DOCKET:

Protein (VCIP)

Ş

D6563

MS DD Commissioner of Patents P.O. Box 1450 Alexandria, VA 22313-1450

CERTIFICATE OF MAILING UNDER 37 C.F.R. 1.8

Dear Sir:

I hereby certify under 37 CFR 1.8 that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to: MS: DD, Commissioner of Patents, P.O. BOX 1450, Alexandria, VA 22313-1450, on the date indicated below.

- 1) Information Disclosure Statement: and
- 2) PTO Form 1449 (Five References cited)

Please return the enclosed postcard acknowledging receipt of this correspondence.

Date: Now 15,0006

ADLER & ASSOCIATES 8011 Candle Lane

Houston, Texas 77071

(713) 270-5391

Fax: (713) 270-5361

BADLER1@houston.rr.com

Respectfully submitted,

Benjamin Aaron Adler, Ph.D., J.D.

Registration No. 35,423 Counsel for Applicant

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Wary et al. § ART UNIT:

FILED: March 29, 2004 §

S EXAMINER:

SERIAL NO.: 10/812,238 §

FOR: Uses of Vascular Endothelial §
Growth Factor and Type 1 §

Collagen Inducible Protein (VCIP) § D6563

MS DD

Commissioner of Patents P.O. BOX 1450 Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97(c)

Dear Sir:

Enclosed herewith for filing under 37 C.F.R. 1.97(c) in the above-referenced matter is form PTO-1449 together with copies of the references listed therein. Applicants state that each item of information contained in the information disclosure statement herein was cited in a communication from a foreign application not more than three months prior to the filing of the information disclosure statement. If any questions remain, the Examiner is respectfully requested to call the undersigned attorney at (713)-270-5391.

Respectfully submitted,

Date: Nov 15, 2006
ADLER & ASSOCIATES

8011 Candle Lane

Houston, Texas 77071

Phone: (713) 270-5391 Fax: (713) 270-5361

BADLER1@houston.rr.com

Benjamin Aaron Adler, Ph.D., J.D.

DOCKET

Registration No. 35,423 Counsel for Applicant NOV 1 7 2006 W

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

DOCKET NO.:

D6563 10/812,238

Information Disclosure Statement SERIAL NO.: APPLICANT:

Wary, et al.

FILING DATE: GROUP:

March 29, 2004

U.S. PATENT DOCUMENTS

Examiner

Document

Name

Class

Subclass

Filing Date

Initial

Number

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Publication: Patent Cooperation Treaty (PCT)

Translation: English

Document Number: WO 98/46730

Date:

Country: Great Britain

Class Or Subclass

C12N 9/16

Patent:

Yes _ No X

Date

Title: Human Phosphatidic Acid Phosphatase

Publication: Patent Cooperation Treaty (PCT)

Translation: English

Document Number: WO 95/28426

Date:

Country: Great Britain

Class Or Subclass

C07K 14/75

Patent:

Yes _

No X

Title: Peptides for Reducing or Inhibition Bone Resorption, Angiogenesis and Restenosis

OTHER DOCUMENTS (Including Author, Title, Place of Date, Publication)

a. Wary, K. K. et al. VCIP Induces Cell-Cell Interactions: Its Role in Angiogenesis: Institute of Biosciences and Technology, November 2002, vol. 13, pp. 75a-76a

_____ b. Schabbert, S. et al. Incorporation of (2S,3S) and (2S,3R) β-Methyl Aspartic Acid into RGD-Containing Peptides: Bioorganic & Medicinal Chemistry, October 2002, vol. 10, no. 10, pp. 3331-3337

c. Humtsoe, J. O. et al.; Regulation of Cell-Cell Interactions by Phosphatidic Acid Phosphatase 2b/VCIP: The EMBO Journal, April 1, 2003 vol. 22, no. 7, pp. 1539-1554

Examiner

Date Considere

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)